CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc., (NASDAQ: RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced financial results for the fourth quarter and year ended December 31, 2016 and provided an update on recent corporate and clinical developments.
“Following our successful initial public offering in October 2016, we are well positioned to advance our lead complement C5 inhibitor, RA101495, and other pipeline programs in 2017,” said Doug Treco, PhD, President and Chief Executive Officer of Ra Pharma. “Having secured approval from the FDA and other ex-U.S. regulatory agencies to initiate our Phase 2 program in PNH patients, we look forward to starting these studies by the end of the first quarter. RA101495 is designed as a convenient self-administered subcutaneous injection, with highly predictable pharmacokinetics and robust pharmacodynamic effects. We believe that it represents an attractive alternative to the current standard of care, which requires regular intravenous infusions and does not adequately address the needs of all PNH patients. We expect to share data from these studies in the second half of this year.”
